Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +1204.0% | -10.6% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +1204.0% over three years. Forward estimates point to Revenue at -10.6% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | $658.71M | $6.28 | Not rated | -9.6 | -28.01% |
Immunic, Inc. NASDAQ:IMUX | $146.05M | $14.80 | Not rated | -4.1 | +7.41% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $123.15M | $5.73 | Not rated | -40.8 | -33.02% |
Fortress Biotech, Inc. NASDAQ:FBIO | $100.99M | $3.04 | Undervalued | 0.7 | -30.04% |
CAMP4 Therapeutics Corporation NASDAQ:CAMP | $94.09M | $4.43 | Not rated | -2.8 | +13.96% |
PMV Pharmaceuticals, Inc. NASDAQ:PMVP | $65.06M | $1.22 | Not rated | -0.8 | +0.00% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $64.74M | $1.06 | Not rated | -1.0 | -16.29% |
Cibus, Inc. NASDAQ:CBUS | $63.23M | $1.39 | Not rated | -8.6 | -2.38% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $54.28M | $1.72 | Not rated | -0.8 | -38.05% |
Continue the stock analysis
Jump to another research area for this company.